Trial Profile
Phase I/IIa Study of RNActive-Derived Therapeutic Vaccine in Metastatic Hormone Refractory Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs CV 9103 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 29 Mar 2012 Actual patient number changed from 10 to 6 as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 10 Feb 2011 Planned end date changed from 1 Sep 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.